CONSEGNA 30/70 INJ 3ML used for the treatment of both type 1 and type 2 diabetes mellitus. It maintains blood sugar levels in adults and children. In Type 1 Diabetes Mellitus, the body does not produce enough insulin to regulate blood sugar levels. In type 2 diabetes mellitus, either the body stops producing enough insulin (a hormone that helps lower blood sugar levels) or there is resistance to the action of insulin. As a result, insulin is produced in large quantities, but it is unable to function properly on the body's organs.

CONSEGNA 30/70 INJ 3ML is a combination medicine that works by promoting the recovery of sugar in muscle and fat cells and suppressing sugar production in the liver. Together, CONSEGNA 30/70 INJ 3ML confirms rapid and stable sugar control.

Not everyone who is taking CONSEGNA 30/70 INJ 3ML will get these side effects. You may experience rash, injection site allergic reaction, weight gain, edema (tissue swelling or fluid overload), skin thickening at the injection site, low blood glucose levels, and itching. Most of these side effects of CONSEGNA 30/70 INJ 3ML do not require medical attention and gradually resolve over time. However, if the side effects are persistent, reach out to your doctor.

CONSEGNA 30/70 INJ 3ML should be taken as advised by your doctor. It should be administered subcutaneously (in the upper thigh, abdomen, upper arm, or buttocks) only. Your doctor will explain how to inject the medicine by your own. However, if it is difficult to inject the medicine, ask a healthcare professional to administer it. Along with CONSEGNA 30/70 INJ 3ML, you should take a healthy diet, do regular exercise, and maintain weight as advised by your doctor.

Inform your doctor if you are allergic to CONSEGNA 30/70 INJ 3ML. Do not take CONSEGNA 30/70 INJ 3ML if you have any low blood glucose levels, kidney, liver, or heart problems, or problems with alcohol or other prescription or recreational drugs. Try not to stop receiving CONSEGNA 30/70 INJ 3ML of your own. Let your doctor know about this, as it may cause withdrawal symptoms. CONSEGNA 30/70 INJ 3ML is a cold chain medicine, and so it must be stored in the refrigerator between 2-8 degrees Celsius, or else its efficiency might get lost. Do not store in the freezer or the fridge.

• Follow your doctor's instructions on the dosage and timing of this medication, to ensure the safety. • CONSEGNA 30/70 INJ 3ML should be administered subcutaneously (in the upper thigh, abdomen, upper arm, or buttocks). • It should never be administered intravenously or in the vein. • If you are not well trained to self-administer it, ask your healthcare professional to administer it.

• CONSEGNA 30/70 INJ 3ML is a combination medicine used for the treatment of both type 1 and type 2 diabetes mellitus. 
• CONSEGNA 30/70 INJ 3ML suppresses the production of sugar in the liver and facilitates the reuptake of sugar in the fat and muscle cells; thereby,
• This medicine ensures rapid and consistent sugar control in your body.
• CONSEGNA 30/70 INJ 3ML helps in improving glycaemic control, which in turn decreases the risk of progression of diabetes like damage of the retina, damage to the kidney, damage to nerve cells, delayed wound healing, diabetic foot ulcer and others.
• The Penfill format facilitates precise and convenient dosing using an insulin pen device, thereby enhancing the ease of use for diabetic patients.

Inform your doctor if you are allergic to CONSEGNA 30/70 INJ 3ML. Do not take CONSEGNA 30/70 INJ 3ML if you have any low blood glucose levels, kidney, liver, or heart problems, or problems with alcohol or other prescription or recreational drugs. Try not to stop receiving CONSEGNA 30/70 INJ 3ML of your own. Let your doctor know about this, as it may cause withdrawal symptoms. CONSEGNA 30/70 INJ 3ML may decrease the level of potassium, leading to a state of hypokalemia that, if left untreated, may lead to respiratory paralysis, irregular heartbeat rhythm, coma, and even death.

CONSEGNA 30/70 INJ 3ML is for subcutaneous (under the skin) use only. If you are switching to a different insulin brand or using a different method of injection, it should be done under strict medical supervision. Cases of heart failure have been reported when pioglitazone was used with insulin, especially in patients at high risk of cardiac heart failure. The first symptoms of hyperglycemia (high blood sugar levels) may include excessive thirst, dry mouth, increased frequency of urination, nausea, vomiting, drowsiness, flushed dry skin, loss of appetite, and an acetone odour in the breath. You should closely monitor these symptoms.

It is advisable not to consume alcohol, as it may either increase or decrease your blood glucose level. Care should be taken while travelling across more than two time zones. Your doctor may adjust your insulin schedule. CONSEGNA 30/70 INJ 3ML is a cold chain medicine, and therefore it must be stored in the refrigerator at a temperature between 2-8 degrees Celsius; otherwise, its efficiency may be compromised. Do not store in the freezer or the fridge.

Keep the medicine out of reach of children. Please do not inject more than the recommended dose of medicine, as it can cause undesirable effects. It is always important to check the expiry date of the medicine. Discard the medicine if it reaches the expiry date. CONSEGNA 30/70 INJ 3ML should not be administered intravenously (into the vein).